Jinggou Biotech Closes Tens of Millions of Yuan in Series A Funding, Dalton Venture Bets on Synthetic Biology for Nutrition and Health | Dalton News
Recently, emerging Chinese synthetic biology company **Hangzhou Jinggou Biotechnology Co., Ltd. (hereinafter referred to as "Jinggou Bio") announced the completion of a Series A financing round worth tens of millions of RMB, with Dalton Venture participating in the investment.** Proceeds from this round will be primarily directed toward R&D investment and production base capacity building, accelerating the scaled production of high-value-added nutritional health and feed additive products, and advancing the commercialization of green bio-manufacturing.
Background
Recently, Hangzhou Jinggou Biotechnology Co., Ltd. ("Jinggou Bio") announced the completion of a Series A financing round worth tens of millions of RMB, with Dalton Venture participating as an investor. The proceeds will primarily fund R&D investments and production base capacity expansion, accelerating the scaled manufacturing of high-value nutritional supplements and feed additives while advancing the commercialization of green biomanufacturing.
Capital Boost Accelerates Synthetic Biology Commercialization
Founded in 2023, Jinggou Bio has rapidly built out and refined five integrated R&D platforms spanning strain development, fermentation, separation, analytics, and pilot-scale production — giving it full-stack capabilities from lab research to mass manufacturing. With strong execution on industrialization, the company has already achieved commercial-scale production of multiple core products including L-citrulline, vitamin K2, L-arginine, L-tryptophan, and L-astaxanthin, and has established stable partnerships with leading downstream enterprises.
As the global synthetic biology industry enters a phase of accelerated growth, Jinggou Bio is expanding its product pipeline with a market-driven, commercialization-focused approach, committed to delivering more competitive green solutions for human nutrition, animal health, and sustainable development.
Investor Perspective: Industrialization Efficiency and Product Selection Foresight Are Core Competitive Advantages
Qi Sun, Founding Managing Partner of Dalton Venture, commented: Competition among synthetic biology companies ultimately comes down to technology conversion efficiency and cost control capabilities. This demands not only top-tier R&D strength but also systematic competence in process scale-up and market development. As investors in this round, we particularly value the founder and team's extensive industry experience and forward-looking product selection capabilities. In just two years since founding, they have efficiently bridged the critical gap from lab research to industrialization. We expect this investment to help the company accelerate commercialization of its core products.
About Jinggou Bio
Hangzhou Jinggou Biotechnology Co., Ltd., founded in 2023, is an innovative company focused on applied synthetic biology technology. Concentrating on essential sectors including human nutrition and feed additives, it aims to build a leading domestic and world-class green biomanufacturing platform.
The company's team brings together top scientific research talent and industrialization experts from synthetic biology and chemical engineering, with full-process capabilities spanning strain R&D, fermentation optimization, separation and purification, process scale-up, and commercial production. Through building out a comprehensive technology and industrial chain, Jinggou Bio has achieved mass production of multiple core products with market validation. Going forward, the company will continue to deepen the application of synthetic biology in nutrition, health, and animal care, driving the industry toward greater efficiency and sustainability.
ID: daltonventure
Long press to follow
Recommended Reading
